Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Doe

Vascular & Interventional Radiology Houston, TX Medical Doctor

NPI 1023158649 CMS profile 136718

1213 Hermann Dr, Suite 255, Houston, TX 77004

Open in the dashboard

General payments

$105,604

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Doe of Houston, TX is reported in the CMS Open Payments database as having received $105,604 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,594 13
2024 General $26,636 34
2023 General $24,680 54
2022 General $14,654 34
2021 General $260 7
2020 General $555 24
2019 General $1,224 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Doe
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Andrew Doe were reported at $37,594. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Andrew Doe Vascular & Interventional Radiology median Middle half National median
2019 $1,224 $422 $125–$1,555 $163
2020 $555 $200 $68–$652 $114
2021 $260 $280 $99–$866 $132
2022 $14,654 $433 $137–$1,497 $149
2023 $24,680 $506 $152–$2,019 $160
2024 $26,636 $556 $175–$1,930 $164
2025 $37,594 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $68,997 30 payments
  2. Uresil LLC $28,375 6 payments
  3. Medtronic, Inc. $4,455 62 payments
  4. Medtronic Vascular, Inc. $1,267 50 payments
  5. Sirtex Medical Inc $692 5 payments
  6. Biotronik Inc. $580 26 payments
  7. Terumo Medical Corporation $405 5 payments
  8. Siemens Medical Solutions USA, Inc. $268 3 payments
  9. Argon Medical Devices, Inc. $158 3 payments
  10. Abbott Laboratories $87 1 payment
  11. Other $319 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $68,125 4 payments
  2. Consulting Fee $28,685 7 payments
  3. Food and Beverage $7,014 182 payments
  4. Travel and Lodging $1,753 10 payments
  5. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $38,125 3 payments
  2. Auryon Laser System 100-120 Vac Cv $30,000 1 payment
  3. ELLIPSYS VASCULAR ACCESS SYSTEM $2,838 37 payments
  4. AURYON LASER SYSTEM 100-120 VAC Pad $872 26 payments
  5. SIR-Spheres Microspheres $692 5 payments
  6. Pulsar-18 T3 $545 25 payments
  7. Passeo-18 $543 23 payments
  8. GLIDESHEATH SLENDER $534 6 payments
  9. HawkOne $472 30 payments
  10. Azur CX Detachable $405 5 payments
  11. Other $4,292 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

30

Median for Interventional Radiology: 38

Drug cost

$345

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 30 $345

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$329,262

Medicare's payments for the services billed

Medicare patients

144

Average age 74

Services billed

833

52 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 44%
Diabetes 42%
Chronic kidney disease 33%
Heart failure 24%
Atrial fibrillation 24%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record